Skip to main content

Fetzima Side Effects

Generic name: levomilnacipran

Medically reviewed by Drugs.com. Last updated on Sep 24, 2023.

Note: This document contains side effect information about levomilnacipran. Some dosage forms listed on this page may not apply to the brand name Fetzima.

Applies to levomilnacipran: oral capsule extended release.

Warning

Oral route (Capsule, Extended Release)

Warning: Suicidal Thoughts and BehaviorsAntidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Levomilnacipran is not approved for use in pediatric patients.

Serious side effects of Fetzima

Along with its needed effects, levomilnacipran (the active ingredient contained in Fetzima) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking levomilnacipran:

More common

Less common

Incidence not known

Other side effects of Fetzima

Some side effects of levomilnacipran may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to levomilnacipran: oral capsule extended release.

General

The most commonly reported side effects included nausea, erectile dysfunction, constipation, and hyperhidrosis.[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 17%)

Common (1% to 10%): Constipation, vomiting

Frequency not reported: Abdominal pain, flatulence[Ref]

Cardiovascular

Common (1% to 10%): Hot flush, hypertension, hypotension, increased blood pressure, increased heart rate, palpitations, tachycardia

Frequency not reported: Angina pectoris, chest pain, increased diastolic blood pressure, increased orthostatic blood pressure, increased orthostatic heart rate response, increased systolic blood pressure, labile hypertension, orthostatic hypotension, postural orthostatic tachycardia syndrome, sinus tachycardia, supraventricular extrasystoles, ventricular extrasystoles

Postmarketing reports: Takotsubo cardiomyopathy[Ref]

Genitourinary

Erectile dysfunction and urinary hesitation occurred as dose-related events.[Ref]

Common (1% to 10%): Ejaculation disorder, erectile dysfunction, testicular pain, urinary hesitation

Frequency not reported: Ejaculation delayed, ejaculation failure, epididymitis, hematuria, organic erectile dysfunction, pollakiuria, proteinuria, seminal vesiculitis, urinary hesitation, urinary retention[Ref]

Dermatologic

Common (1% to 10%): Hyperhidrosis, rash

Frequency not reported: Dry skin, erythematous rash, generalized rash, macular rash, maculopapular rash, pruritus, urticaria[Ref]

Metabolic

Common (1% to 10%): Decreased appetite

Frequency not reported: Hyponatremia, increased blood cholesterol, thirst[Ref]

Psychiatric

Frequency not reported: Aggression, agitation, anger, bruxism, hypomania activation, mania activation, panic attack, premature ejaculation, psychogenic erectile dysfunction, suicidal behaviors, suicidal thoughts, tension[Ref]

Suicidal thoughts and behaviors more commonly occurred in adolescent and young adults 24 years and younger.[Ref]

Nervous system

Frequency not reported: Extrapyramidal disorder, migraine, paresthesia, postural dizziness, seizure, serotonin syndrome, syncope[Ref]

Ocular

Frequency not reported: Angle closure glaucoma, blurred vision, conjunctival hemorrhage, dry eye[Ref]

Other

Frequency not reported: Discontinuation syndrome[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity[Ref]

Hematologic

Frequency not reported: Increased bleeding risk[Ref]

Hepatic

Frequency not reported: Abnormal liver function tests[Ref]

Respiratory

Frequency not reported: Yawning[Ref]

Frequently asked questions

References

1. Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals. 2013.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.